Chemical Composition and Antiproliferative Activity of Supercritical CO2 Extracts from Citrus Fruits

Gyawali, Rajendra; Moon, Jeong Yong; Jeon, Deok Hyeon; Kim, Hyoen Ji; Song, Yeon Woo; Hyun, Ho Bong; Kang, Tae Hwan; Moon, Keun Sik; Jeong, Seung-Weon; Kim, Jong-Chan; Ahn, Kwang Seok; Cho, Somi Kim

doi:10.3136/fstr.18.813

Cited by 6 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a typical species of TCM, Exocarpium Citri Grandis (ECG) is known for its significant curative effects on pneumonic symptoms ( China CftPoPsRo Committee for the Pharmacopoeia of People’s Republic of China, 2010 ). The most beneficial properties of ECG are strongly associated with its anti-oxidation ( Tao and Liu, 2012 ), anti-bacterial ( Jayaraman et al, 2012 ), and immunoregulation ( Gyawali et al, 2012 ) properties. Composed of eight active ingredients, including ECG (a key constituent), the Juhongtanke oral solution (XiangXue Pharmaceutical Co. Ltd., Guangdong, China) is widely used in clinical practice in China.…”

Section: Introductionmentioning

confidence: 99%

Effects of Juhongtanke oral solution on alleviating the symptoms of community-acquired pneumonia: A multicenter, prospective, randomized controlled trial

Liang¹,

Hu²,

Luo³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Introduction: The timely alleviation of symptoms is essential for managing community-acquired pneumonia (CAP). Juhongtanke oral solution is a traditional marketed Chinese patent medicine believed to ease CAP symptoms. The currently available evidence is based on a few retrospective studies of patients with various types of pneumonia, whereas robust randomized controlled trials (RCTs) that support this notion are lacking.Material and methods: In this multi-center, prospective RCT, patients were randomly allocated to receive routine treatment alone or a combination of Juhongtanke oral solution (20 mL q8h) for 5 days and maintained for an additional 3-day safety observation period. The primary outcome was Breathlessness, Cough, and Sputum Scale (BCSS) score evaluated on day 5. Secondary outcomes included the evaluation of cough and dyspnea items in the Visual Analogue Scale (VAS) from days 1–5, remission rate in BCSS and VAS during the treatment course, and the length of hospitalization and in-hospital mortality.Results: Of 272 patients assessed for eligibility, 240 were enrolled in the study (n =120 per group). The mean difference in BCSS evaluated on day 5 was a median 1 point [95%CI (1.00, 2.00)], significantly lower in the treatment group compared with the control group (p < 0.001). Similar results were observed in VAS on day 5, with statistics of a median 2 points [95%CI (1.40, 2.50)] in the cough item and a median 1 point [95%CI (0.50, 2.00)] in the dyspnea item, significantly lower in the treatment group compared with the control group (both p < 0.001). The treatment group had a favorable outcome in BCSS and VAS remission rate assessments compared with the control group, with 99.50% vs. 89.17% in BCSS (p = 0.01), 98.33% vs. 75% in the cough item of VAS (p < 0.001), and 88.33% vs. 62.50% in the dyspnea item of VAS (p < 0.001), respectively. No notable adverse effects were observed during the study. No differences were observed in the length of hospitalization between groups (with a median of 7 days for both groups, p = 0.871).Conclusion: Juhongtanke oral solution may be considered to alleviate the clinical symptoms of CAP.

show abstract

Section: Introductionmentioning

confidence: 99%